Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida. Show more

Location: Life Science & Technology Park, Miami, FL, 33136, United States | Website: https://longeveron.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

21.31M

52 Wk Range

$1.14 - $4.88

Previous Close

$1.50

Open

$1.50

Volume

559,680

Day Range

$1.36 - $1.55

Enterprise Value

6.48M

Cash

14.33M

Avg Qtr Burn

-3.87M

Insider Ownership

7.45%

Institutional Own.

8.78%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lomecel-B (laromestrocel) Details Pediatric Dilated Cardiomyopathy (DCM)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lomecel-B (laromestrocel) Details Hypoplastic Left Heart Syndrome	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lomecel-B (laromestrocel) Details Alzheimer's disease	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lomecel-B Details Aging Frailty	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lomecel-B Details Acute respiratory distress syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.